



## **X4 Pharmaceuticals to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference**

September 7, 2016

**CAMBRIDGE, Mass., September 7, 2016** – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the 23<sup>rd</sup> Annual BioCentury NewsMakers in the Biotech Industry Conference in New York on Friday, September 9, 2016 at 8:30 a.m. ET.

### **About X4 Pharmaceuticals**

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The company's oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in immune surveillance. X4P-001, the company's lead program, is in Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications. The company's second program, X4P-002, is in pre-clinical development for oncology applications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.